Atara Biotherapeutics

Atara Biotherapeutics, Memorial Sloan-Kettering Cancer Center ink agreement

Wednesday, September 24, 2014

Atara Biotherapeutics, a California-based, privately held drug development company, has entered into an exclusive option agreement with New York’s Memorial Sloan Kettering Cancer Center (MSK) for the development and commercialization of allogeneic T-cell therapies for the treatment of certain cancers and persistent viral infections. Atara will have the option to acquire a worldwide license to three clinical stage T-cell therapies, consisting of:

[Read More]